abs86.txt	purpose		the	ability	to	predict	and	detect	clinical	subclinicalnephrotoxicity	early	in	course	of	therapy	has	potential	improvelong-term	outcomes	cancer	patients	receiving	cisplatin	chemotherapy	pharmacokinetic	parameters	could	serve	as	predictors	cisplatin-inducednephrotoxicity	methods	participants	[n	=	13]	were	treated	with	a	1-h	infusion[30-75	mg/m2]	blood	was	collected	pre-dose	up	6	h	post-dose	urinarybiomarkers	[kim-1	calbindin	clusterin	gst-pi	Î²2m	albumin	ngal	osteopontin	mcp-1	cystatin	c	tff3]	measured	at	baseline	days	3	10	total	unbound	platinum	concentrations	using	icp/ms	noncompartmental	analysis	performed	correlation	regression	analysesevaluated	relationships	between	pharmacokinetics	nephrotoxicity	results	peak	urinary	correlated	levels	ofkim-1	tff3	day	plasma	2	halso	andtff3	analyses	suggested	2-h	platinumconcentrations	greater	than	2000	ng/ml	concentrationsabove	24	000	may	approximations	for	elevated	risk	ofnephrotoxicity	area	under	concentration	time	curve	wasassociated	serum	creatinine	estimated	glomerular	filtration	rate	conclusions	pharmacokineticparameters	associated	subclinical	cisplatin-induced	kidneyinjury	assessed	novel	biomarkers	future	studies	will	examinethese	larger	populations	acutekidney	injury
